A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors

In brief

To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.

Key facts

Study ID

NCT01248949

Run by

MedImmune LLC

People needed

162

Starts

2010-10-01

Expected to finish

2015-10-01

Last updated by the study team

2017-03-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with confirmed diagnosis of advanced solid tumors (dose-escalation phase) or another solid tumor type based on antitumoral activity (dose-expansion phase) that are not responsive to standard therapy or for which no standard therapy exists
• Patients must be 18 years of age or older
• Karnofsky Performance Status ≥ 70
• Toxicities from previous cancer therapies must have recovered to CTCAE Grade = or < 2
• Adequate organ and marrow function
• Using adequate contraceptive measures, be surgically sterile or post-menopausal

You may not qualify if…

• Concurrently enrolled in another clinical study, except for non-interventiona observational studies, or if in a follow up period from a previous study
• Receipt of any investigational anticancer therapy within 30 days prior to the first dose of MEDI3617, or in the case of monoclonal antibodies (eg, bevacizumab), 42 days prior to the first dose of MEDI3617
• Current or previous treatment with angiopoietin inhibitors, or inhibitors of Tie1 or Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820
• Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment
• Use of immunosuppressive medication or systemic steroids within 7 days prior to first dose of MEDI3617
• Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
• Known bleeding diathesis
• Pulmonary hemorrhage or gross hemoptysis within 6 months prior to enrollment
• Therapeutic or palliative radiation therapy within 2 weeks prior to enrollment

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — Stanford, California, United States
• Research Site — Lafayette, Indiana, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Buffalo, New York, United States
• Research Site — New York, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.